Chinese patent medicine "Le Mai Granule" is approved to be listed in Canada for the first time!

Source: Eternal Huaxi 2017-12-04 lesoheme granule (Canadian Name: vasoheme) has been used in the treatment of cardiovascular and cerebrovascular diseases in China Since its successful development, it has served patients for 24 years and won high praise in the Chinese traditional medicine market After eight years of application and approval, vasoheme became the first Chinese patent medicine product successfully registered and listed in Canada in the form of drugs rather than health products in 2017 It is the first time for Chinese medicine products to enter the international market in the form of therapeutic Chinese medicine It is the beginning of Chinese medicine entering the mainstream market of western advanced countries The launch press conference of vasoheme was held in Markham yesterday Chinese and Western medicine experts and politicians from Canada, Hong Kong, West China hospitals and pharmaceutical factories respectively expressed warm congratulations and good wishes on this milestone Professor Li tingqian of Huaxi Hospital specially attended the press conference, gave a lecture on the pharmacology, preparation and clinical research of vasoheme, and answered the questions raised by the participants on the spot.